# Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yi‐Long Wu,Ying Cheng,Xiangdong Zhou,Ki Hyeong Lee,Kazuhiko Nakagawa,Seiji Niho,Fumito Tsuji,R. Linke,Rafael Rosell,J. Corral,Maria Rita Migliorino,Adam Płużański,Eric Sbar,Tao Wang,Jane Liang White,Sashi Nadanaciva,Rickard Sandin,Tony Mok |
| Citations | 1,219 |
| DOI | 10.1016/s1470-2045(17)30608-3 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2760639821 |
| PMID | 28958502 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)
- [Seiji Niho](https://scholariq.org/researchers/seiji-niho/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Maria Rita Migliorino](https://scholariq.org/researchers/maria-rita-migliorino/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.